Severin Schwan has been a huge influence in the business of targeted cancer drugs and the understanding of medical diagnostics – indeed, it is worth noting that not all pharma chiefs are willing to pump as much money as Roche into diagnostics and gene sequencing platforms.
Along the innovation lines, Schwan has honoured a tradition at Roche of diligent exploration of diseases and development of new drugs since taking over as CEO in 2008.
The company’s R&D efforts have positioned the company to bring a slate of potential blockbusters to market, including its celebrated cardiovascular drug dalcetrapib.
Latest Tweets
Tweets by TwitterDev